ABOUT CYTOVANCE BIOLOGICS
Cytovance® Biologics is a biopharmaceutical contract manufacturing company specializing in the production of therapeutic proteins and antibodies from both mammalian cell culture and microbial fermentation. In addition to its cGMP manufacturing services, the company offers process development, cGMP cell banking and support services from its state-of-the-art Oklahoma City facilities.
Our Mission Statement
Cytovance® Biologics' mission is to become a valuable partner to our clients by providing an integral pathway in converting today's novel protein discoveries into future lifesaving therapies and diagnostics. Cytovance® is your partner in the biopharmaceutical contract manufacturing of therapeutic proteins and antibodies from mammalian cell culture and microbial fermentation.
At Cytovance®, we provide unparalleled support to biopharmaceutical companies to move new, safe medicines from the lab bench to those who need them most. We’re committed to a healthier world. Cytovance® offers a comprehensive range of development and cGMP manufacturing services, including:
CONTACT INFORMATION
Cytovance Biologics
800 Research Parkway, Suite 200
Oklahoma City, OK 73104
Midway Islands
Phone: 405-319-8310
Contact: Montressa Goodloe-Ruffin, Client Relationship Manager
VIDEOS AND WEBINARS
- Cytovance Biologics Capacity Update October 2024: Large Molecule Drug Substance
- Cytovance Capacity Update July 2024: Large Molecule Development
- Transforming Data Into Knowledge Throughout The Product Lifecycle
- Production Of Therapeutic Proteins In CHO Cells
- Accelerating Biologics Drug Development With An Analytical Toolkit
- Scale-Up Strategies: Mammalian, Microbial Process Commonalities
- Cytovance Biologics Analytical Development Services
POSTERS
- Conversion Of A Viral Glycoprotein Titer Method From ELISA To BLI
- Identification And Risk Mitigation Of A Critical Process Parameter During Antibody Process Scale-Up
- DSD For The icIEF Assay Development Of Antibodies, Therapeutic Proteins
FEATURED ARTICLES
-
Navigate the challenging path from concept to clinical reality by partnering with an experienced CDMO that can provide the regulatory, clinical, and CMC expertise needed to move your therapeutic forward and bring it closer to patients in need.
-
For emerging biotechs looking to refine their development processes and boost their chances of commercial success, exploring these partnership opportunities could prove invaluable.
-
Learn more about the cutting-edge technologies driving the shift to microbial expression and how the right outsourcing partner can help you leverage the benefits of these innovative therapeutics.
-
Discover how whether you’re trying to achieve speed and cost-effectiveness or higher yields and glycosylation capabilities, the right system can be tailored to meet the needs of each unique biologic.
-
By partnering with a trusted company that offers expertise in navigating the challenges of scale up, drug developers can have confidence in their ability to successfully bring their products to market.
-
Learn how AI is transforming the biomanufacturing industry and how partnerships between pharmaceutical companies and academic institutions are poised to set the new standard.
-
The predictive models created using “self-validating ensemble modeling (SVEM)” on the definitive screening design data reliably predicted the behavior of the chosen responses.
-
In this case study, the analytical development group was provided an ELISA titer method, and the method was redeveloped to operate by biolayer interferometry (BLI) using the ForteBio Octet RED96.
-
The case study presented here involved the production of a Phase 1 clinical trial material at a100 L scale with limited process development prior to cGMP production and productivity of <1 g/L. A scale-up to 1,000 L was planned for a Phase 2 clinical supply, with an initial 1,000 L batch being successful with similar yield to 100 L batches.
-
Fragment crystallizable (Fc)-fusion proteins are a growing class of biopharmaceuticals that have gained popularity due to the manufacturability benefits and extended drug half-life afforded by the Fc fragment. This case study focuses on one such fusion protein, consisting of a protein receptor fused to a human IgG Fc fragment.
-
Waiting to integrate GMP can lead to time delays and unnecessary costs. Find out how a new approach to phase-appropriate GMPs can help manufacturers navigate today's regulatory landscape with confidence.
-
While manufacturing training typically takes years, a Cytovance Biologics methodology developed in partnership with academia resulted in a fully-functional biotech floor team in under 3 months.
-
Cells grew in the lab, but wouldn't grow in an outsourced working cell bank. Here's how a contract manufacturer turned around the repeated failure of a client's master cell bank-to-working cell bank transfer.